Search results for "Mace"

showing 10 items of 4713 documents

PEG 400/Cerium Ammonium Nitrate Combined with Microwave-Assisted Synthesis for Rapid Access to Beta-Amino Ketones. An Easy-to-Use Protocol for Discov…

2018

Compound libraries are important requirement in target-based drug discovery. In the present work, a small focused compound library based on β-aminoketone scaffold has been prepared combining microwave-assisted organic synthesis (MAOS) with polymer-assisted solution phase synthesis (PASPS) and replacing reaction workup standard purification procedures with solid phase extraction (SPE). Specifically, the effects of solvent, such as dioxane, dimethylformamide (DMF), polyethylene glycol 400 (PEG 400), temperature, irradiation time, stoichiometric ratio of reagents, and catalysts (HCl, acetic acid, cerium ammonium nitrate (CAN)) were investigated to maximize both conversion and yield. The optimi…

3003Transcription FactorPharmaceutical ScienceNitratePolyethylene Glycol01 natural sciencesPolyethylene GlycolsPolymer-assisted solution phase synthesiAnalytical Chemistrychemistry.chemical_compoundDrug DiscoveryMannich reactionSolid phase extractionMicrowavesβ-aminoketonesCeriumKetonesKetoneDNA-Binding ProteinsSolventCeriumChemistry (miscellaneous)Molecular MedicineDimethylformamideMicrowave-assisted organic synthesiMannich reaction; β-aminoketones; microwave-assisted organic synthesis; polymer-assisted solution phase synthesis; solid phase extraction; drug discoveryDNA-Binding ProteinBacterial Proteinchemistry.chemical_elementPolyethylene glycol010402 general chemistryArticlelcsh:QD241-441Bacterial Proteinslcsh:Organic chemistryΒ-aminoketonePhysical and Theoretical ChemistrySolid phase extractionpolymer-assisted solution phase synthesisPEG 400Nitrates010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistrySettore CHIM/08 - Chimica FarmaceuticaCombinatorial chemistry0104 chemical scienceschemistryYield (chemistry)microwave-assisted organic synthesisOrganic synthesisMicrowaveTranscription FactorsMolecules
researchProduct

Enhanced adhesion and in situ photothermal ablation of cancer cells in surface-functionalized electrospun microfiber scaffold with graphene oxide

2017

The physicochemical characteristics of a biomaterial surface highly affect the interaction with living cells. Recently, much attention has been focused on the adhesion properties of functional biomaterials toward cancer cells, since is expected to control metastatic spread of a tumor, which is related to good probability containing the progression of disease burden. Here, we designed an implantable poly(caprolactone)-based electrospun microfiber scaffold, henceforth PCLMF-GO, to simultaneously capture and kill cancer cells by tuning physicochemical features of the hybrid surface through nitrogen plasma activation and hetero-phase graphene oxide (GO) covalent functionalization. The surface i…

3003business.product_categoryCancer therapyPharmaceutical ScienceNanotechnologyBiocompatible Materials02 engineering and technologyCell capture010402 general chemistry01 natural scienceslaw.inventionPlasmalawNeoplasmsMicrofiberCell AdhesionHumansCell adhesionGraphene oxideHybrid materialChemistryGrapheneBiomaterialOxidesAdhesionPhotothermal therapyPhototherapy021001 nanoscience & nanotechnology0104 chemical sciencesPolycaprolactoneCancer cellMCF-7 CellsSurface modificationGraphite0210 nano-technologybusiness
researchProduct

Widening use of dexamethasone implant for the treatment of macular edema

2017

Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo Department of Ophthalmology, University of Catania, Catania, Italy Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of effica…

3003intravitrealgenetic structuresimplantmedicine.medical_treatmentPharmaceutical ScienceVitrectomyReviewDrug Implantcorticosteroids0302 clinical medicineGlucocorticoidCentral retinal vein occlusionDrug DiscoveryDelayed-Action PreparationCorticosteroidRandomized Controlled Trials as TopicDrug ImplantsCorticosteroids; Dexamethasone; Implant; Intravitreal; Macular edema; Pharmacology; 3003; Drug Discovery3003 Pharmaceutical ScienceDiabetic retinopathyIntravitreal InjectionsUveitismedicine.drugHumanmedicine.medical_specialtydexamethasone03 medical and health sciencesOphthalmologymedicineHumansMacular edemaGlucocorticoidsDexamethasonePharmacologyMacular edemaDiabetic Retinopathybusiness.industryIntravitreal InjectionDrug Discovery3003 Pharmaceutical Sciencelcsh:RM1-950Macular degenerationmedicine.diseaseeye diseasesSurgerylcsh:Therapeutics. PharmacologyDelayed-Action Preparations030221 ophthalmology & optometryBranch retinal vein occlusionsense organsbusiness030217 neurology & neurosurgeryDrug Design, Development and Therapy
researchProduct

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

2018

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in Western countries, accounting for 20–30% of general population and reaching a prevalence of 55% in patients with type 2 diabetes mellitus (T2DM). Insulin resistance plays a key role in pathogenic mechanisms of NAFLD. Many drugs have been tested but no medications have yet been approved. Antidiabetic drugs could have a role in the progression reduction of the disease. The aim of this review is to summarize evidence on efficacy and safety of antidiabetic drugs in patients with NAFLD. Metformin, a biguanide, is the most frequently used drug in the treatment of T2DM. To date 15 randomized controlled t…

3003medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentlcsh:Medicinelcsh:RS1-441Pharmaceutical Sciencehepatic cirrhosis030209 endocrinology & metabolismReviewChronic liver diseaseGastroenterologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusDrug DiscoverymedicineBiguanidebusiness.industryLiraglutideInsulinlcsh:RFatty liverThiazolidinedionenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseLiraglutidemedicine.diseaseMetforminMetforminHepatic cirrhosiMolecular Medicine030211 gastroenterology & hepatologyThiazolidinedionesnon-alcoholic steatohepatitisbusinessNon-alcoholic steatohepatitimedicine.drugPharmaceuticals (Basel, Switzerland)
researchProduct

Gold nanostar–polymer hybrids for siRNA delivery: Polymer design towards colloidal stability and in vitro studies on breast cancer cells

2017

To overcome the low bioavailability of siRNA (small interfering RNA) and to improve their transfection efficiency, the use of non-viral delivery carriers is today a feasible approach to transform the discovery of these incredibly potent and versatile drugs into clinical practice. Polymer-modified gold nanoconstructs (AuNCs) are currently viewed as efficient and safe intracellular delivery carriers for siRNA, as they have the possibility to conjugate the ability to stably entrap and deliver siRNAs inside cells with the advantages of gold nanoparticles, which can act as theranostic agents and radiotherapy enhancers through laser-induced hyperthermia. In this study, AuNCs were prepared by coat…

3003siRNA deliverySmall interfering RNAPolymersMetal NanoparticlesPharmaceutical ScienceGold Colloid02 engineering and technologyPolyethylene Glycol01 natural sciencesPolyethylene GlycolsGold Colloidchemistry.chemical_compoundDrug Delivery SystemsMCF-7 CellDrug StabilityCoatingRNA Small InterferingPolymerDrug Carrierchemistry.chemical_classificationDrug CarriersTumorLipoic acidGold nanostarPolymer021001 nanoscience & nanotechnologyColloidal goldMCF-7 Cells0210 nano-technologyDrug carrierHydrophobic and Hydrophilic InteractionsBreast NeoplasmHumanBiological AvailabilityReproducibility of ResultBreast NeoplasmsNanotechnologyPolyethylene glycolengineering.materialSmall InterferingTransfection010402 general chemistryCell LineHydrophobic and Hydrophilic InteractionMetal NanoparticleCell Line TumorAmphiphileHumansGene SilencingParticle SizeGold nanostarsReproducibility of ResultsGold nanostars; Lipoic acid; MCF-7; PEG; PHEA; siRNA delivery; Biological Availability; Breast Neoplasms; Cell Line; Tumor; Drug Carriers; Drug Delivery Systems; Drug Stability; Gene Silencing; Gold; Gold Colloid; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Metal Nanoparticles; Particle Size; Polyethylene Glycols; Polymers; RNA; Small Interfering; Reproducibility of Results; Transfection; 3003PHEAPEG0104 chemical scienceschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoengineeringRNAGoldMCF-7Drug Delivery SystemInternational Journal of Pharmaceutics
researchProduct

Medium-Term Culture of Primary Oral Squamous Cell Carcinoma in a Three-Dimensional Model: Effects on Cell Survival Following Topical 5-Fluororacile D…

2012

Since the activity of several conventional anticancer drugs is restricted by resistance mechanisms and dose-limiting side-effects, the design of formulations for local application on malignant lesions seems to be an efficient and promising drug delivery approach. In this study, the effect of locally applied 5-FU on cell death was evaluated both in a SCC4/HEK001 model and in a newly proposed 3D outgrowth model of oral squamous cell carcinoma (OSCC). Initially, the optimal drug dose was established by delivery of solutions containing different amounts of 5-FU. The solution containing 1% (w/v) of 5-FU resulted effective in inducing cell death with complete eradication of cell colonies. Buccal …

3D OutgrowthSettore BIO/16 - Anatomia UmanaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSettore MED/28 - Malattie Odontostomatologiche3D Outgrowths; OSCC; 5-FU; Matrix tabletsOSCC5-FUMatrix tablets
researchProduct

3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery.

2021

3D printing has been widely used for the personalization of therapies and on-demand production of complex pharmaceutical forms. Recently, 3D printing has been explored as a tool for the development of topical dosage forms and wound dressings. Thus, this review aims to present advances related to the use of 3D printing for the development of pharmaceutical and biomedical products for topical skin applications, covering plain dressing and products for the delivery of active ingredients to the skin. Based on the data acquired, the important growth in the number of publications over the last years confirms its interest. The semisolid extrusion technique has been the most reported one, probably …

3d printedmedicine.medical_specialtyResearch groupsFDM3D-printingAdditive manufacturingLife qualityPharmaceutical ScienceSkin disordersReviewwound dressingfilmPersonalizationImpressão tridimensionalPharmacy and materia medicamedicineMedical physicspatchDermatopatiasFilmAcneActive ingredientbusiness.industrymedicine.diseaseTreatment efficacyRS1-441skin disordersWound dressingDrug deliveryPatchbusinessTerapia [Ferimentos e lesões]additive manufacturingPharmaceutics
researchProduct

NEW 4-DIAZOPYRAZOLE DERIVATIVES AS POTENTIAL ANTIBIOFILM AGENTS

2010

Many infections such as otitis media, sinusitis, cholesteatoma, tonsillitis and adenoiditis are caused by biofilm forming mucosal pathogens (P. aeruginosa, S. aureus, S. peneomoniae, H. influenzae and M. catarrhalis). Moreover, the role of biofilms in the chronic otolaryngologic infections has been recognized for otitis media, tonsillitis and rhinosinusitis. Finally, bacterial biofilms of S. aureus, S. epidermis and E. faecalis are the leading cause of medical device-related infections. Pathogens growing as biofilms are intrinsically resistant to conventional antibiotics and therefore the discovery of new compounds able to act against biofilm aggregated micro organisms is an urgent task. Pr…

4-diazopyrazoles antibiofilm agentsSettore BIO/19 - Microbiologia GeneraleSettore CHIM/08 - Chimica Farmaceutica
researchProduct

7-Azaindole-fused heterocycles with antitumor activity

2011

7-Azaindole- fused hetrocycles7-Azaindole- fused hetrocycle7-Azaindole- fused hetrocycles; DNA-intercalating; Antitumor activityDNA-intercalatingSettore CHIM/08 - Chimica FarmaceuticaAntitumor activity
researchProduct

Unexpected Behavior of Enaminones: Interesting New Routes to 1,6-Naphthyridines, 2-Oxopyrrolidines and Pyrano[4,3,2-de][1,6]naphthyridines

2012

Reaction of enaminones 1a–d with 2-aminoprop-1-ene-1,1,3-tricarbonitrile (2) in the presence of AcOH/NH4OAc afforded 7-amino-5-oxo-5,6-dihydro-1,6-naphthyridine-8-carbonitrile derivatives 9a–d. On the other hand, 2-aminopyrano[4,3,2-de] [1,6]naphthyridine-3-carbonitriles 20a–c,e were the only obtained products from the reactions of 1a–d with 2 in the presence of AcOH/NaOAc, while 1d afforded [3,5-bis-(4-chloro-benzoyl)-phenyl]-(4-chloro-phenyl)-methanone 21 under the same condition. The reaction of 2 with diethyl acetylenedicarboxylate in the presence of AcOH/NH4OAc afforded (4-cyano-5-dicyanomethylene-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-acetic acid eth…

7-amino-5-oxo-56-dihydro-16-naphthyridine-8-carbonitrileMagnetic Resonance Spectroscopy2-aminoprop-1-ene-113-tricarbonitrileMolecular StructureChemistryOrganic ChemistryPharmaceutical ScienceEthyl esterMedicinal chemistryArticleAnalytical Chemistrylcsh:QD241-441Diethyl acetylenedicarboxylate3-amino-2-cyanopent-2-enedinitrilelcsh:Organic chemistryChemistry (miscellaneous)enaminonesNitrilesDrug DiscoveryTransition TemperatureMolecular Medicineenaminones; 3-amino-2-cyanopent-2-enedinitrile; 7-amino-5-oxo-56-dihydro-16-naphthyridine-8-carbonitrile; 2-aminoprop-1-ene-113-tricarbonitrileNaphthyridinesPhysical and Theoretical ChemistryMolecules
researchProduct